Apellis Pharmaceuticals, Inc. Logo

Apellis Pharmaceuticals, Inc.

Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.

APLS | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
100 FIFTH AVENUE, 2451 WALTHAM
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Apellis Pharmaceuticals, Inc. is a global, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds. The company leads in the science of the complement cascade, pioneering targeted C3 therapies to treat a broad range of debilitating diseases driven by uncontrolled or excessive activation of this part of the immune system. Apellis aims to develop transformative treatments for serious conditions in areas such as ophthalmology, nephrology, and hematology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Apellis Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Apellis Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Apellis Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MESOBLAST LTD Logo
Develops off-the-shelf cellular medicines for complex inflammatory and chronic diseases.
United States of America
MESO
Metagenomi, Inc. Logo
Discovering novel gene editing tools from nature for curative genetic medicines.
United States of America
MGX
MetaVia Inc. Logo
A clinical-stage biotech developing novel drugs for cardiometabolic diseases like obesity and MASH.
United States of America
MTVA
Metsera, Inc. Logo
Develops potent, long-acting oral & injectable therapies for obesity & metabolic diseases.
United States of America
MTSR
Mezzion Pharma Co., Ltd. Logo
Develops and out-licenses novel therapeutics like udenafil, with a focus on rare diseases.
South Korea
140410
MFC Co., Ltd. Logo
A GMP-certified CDMO/CMO developing and manufacturing APIs for the global pharma sector.
South Korea
432980
Milestone Pharmaceuticals Inc. Logo
Developing a self-administered nasal spray for at-home treatment of acute cardiac events.
United States of America
MIST
MIMEDX GROUP, INC. Logo
Provides placental-based biologics for advanced wound care, surgical, and burn applications.
United States of America
MDXG
Mind Medicine (MindMed) Inc. Logo
Developing psychedelic-inspired medicines and novel therapies for brain health disorders.
United States of America
MNMD
Mineralys Therapeutics, Inc. Logo
Developing targeted treatments for hypertension & CKD driven by elevated aldosterone.
United States of America
MLYS

Talk to a Data Expert

Have a question? We'll get back to you promptly.